{"DataElement":{"publicId":"4463701","version":"1","preferredName":"Patient Chemotherapy Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to patient determination of eligibility in reference to use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"CHEMO_ED_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3104392","version":"1","preferredName":"Patient Chemotherapy Eligibility Determination","preferredDefinition":"information related to patient determination of eligibility in reference to use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"2233604v1.0:3104390v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3104390","version":"1","preferredName":"Chemotherapy Eligibility Determination","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C15632:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87FBD7AF-FF5B-BBC7-E040-BB89AD43112A","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCIC CRF:National Cancer Institute of Canada Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87FBD7AF-FF6C-BBC7-E040-BB89AD43112A","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has patient received daily or","type":"Preferred Question Text","description":"Has patient received daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient received chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient received chemotherapy less than 3 weeks prior to registration?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient received prior systemic chemotherapy for the current cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has received prior Docetaxel, is patient anticipated to have maintained taxane sensitivity?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Has patient received platinum-based therapy with or without bevacizumab, but may not have received a PD-1, PD-L1 or PD-L2 inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Has patient received any non-platinum regimens or has platinum sensitive disease that is past the first or second recurrence?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has patient received any non-platinum regimens?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Has patient received chemotherapy within 4 weeks prior to entering study?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient received prior paclitaxel in metastatic setting within 2 years prior to Radium-223 dichloride start?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient received platinum-based therapy with or without bevacizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient has pancreatic cancer, has patient received prior platinum-containing therapy in the metastatic setting?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient is enrolled in the Dose Escalation Cohort, has patient received less than three lines of cytotoxic chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient received at least one line of systemic chemotherapy for either locally advanced or metastatic disease and has either progressed on this therapy or been intolerant to this therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has the patient had chemotherapy (including antibody drug therapy) within 4 weeks with the following exceptions:  1 week for weekly paclitaxel; 2 weeks or five half-lives, whichever is longer, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, hormonal agents; or 6 weeks for nitrosoureas or mitomycin C?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient met at least one of the following: 1) received prior platinum containing chemotherapy and/or 2) tumor expresses PD-L1 (Combined Positive Score [CPS] greater than or equal to 1)?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Will dose of pegaspargase or calaspargase pegol be greater than or equal to 1,000 IU/ m2?","url":null,"context":"COG"},{"name":"NRG CRF_Text_1","type":"Alternate Question Text","description":"Are they eligible for further platinum-based therapy?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"018EB20D-77E4-F12A-E050-BB89AD437B1B","latestVersionIndicator":"Yes","beginDate":"2014-08-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-26","modifiedBy":"KUMMEROA","dateModified":"2022-12-21","changeDescription":"9591_Theradex_ghd_08-26-14","administrativeNotes":"2022.12.21 AQT added per ticket request CADSR0001812. ak 2022.11.4 AQT added for ticket request CADSR0001656. ak","unresolvedIssues":null,"deletedIndicator":"No"}}